Interstitial Pneumonia

Interstitial pneumonia is a form of diffuse lung disease characterized by inflammation and/or fibrosis of the pulmonary interstitium, which includes the alveolar walls, peribronchovascular connective tissue, and interlobular septa. It is a common radiographic and histopathologic pattern in dogs and cats, often resulting from a variety of infectious, toxic, or idiopathic causes. The disease can be acute or chronic, and may progress to irreversible fibrosis with impaired gas exchange. Clinically, it manifests as tachypnea, dyspnea, cough (especially in cats), and hypoxemia. Interstitial pneumonia is distinct from alveolar pneumonia, which primarily involves airspace filling, and from bronchopneumonia, which centers on airways. The condition is often classified based on etiology (e.g., viral, bacterial, fungal, parasitic, toxic, or idiopathic) and histopathologic pattern (e.g., diffuse alveolar damage, organizing pneumonia, or chronic interstitial fibrosis).

The etiology of interstitial pneumonia is diverse and includes infectious agents, toxins, and idiopathic causes. Viral causes are common in dogs and cats: canine distemper virus (CDV), canine adenovirus type 2 (CAV-2), canine influenza virus, feline calicivirus (FCV), feline herpesvirus type 1 (FHV-1), and feline infectious peritonitis (FIP) coronavirus. Bacterial causes include Mycoplasma spp., Bordetella bronchiseptica, Streptococcus zooepidemicus, and secondary bacterial infections following viral damage. Fungal causes include Pneumocystis spp. (especially in immunocompromised animals), Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, and Aspergillus spp. Parasitic causes include Toxocara canis (larval migration), Strongyloides stercoralis, and Dirofilaria immitis (heartworm) in aberrant migration. Toxic causes include paraquat, bleomycin, amiodarone, and inhalation of noxious gases (e.g., chlorine, smoke). Idiopathic causes include pulmonary fibrosis (especially in West Highland White Terriers and cats), and interstitial lung diseases of unknown origin. Autoimmune or immune-mediated mechanisms may also play a role in some cases, such as systemic lupus erythematosus or drug-induced hypersensitivity.

Interstitial pneumonia occurs in both dogs and cats, with no strong breed predilection overall, but certain breeds are predisposed to specific forms. West Highland White Terriers are predisposed to idiopathic pulmonary fibrosis (IPF), a chronic interstitial pneumonia. In cats, IPF is seen in older cats, with no breed predilection. Viral interstitial pneumonia is more common in young, unvaccinated animals, especially in shelters or high-density populations. Fungal pneumonias are geographically restricted: histoplasmosis is common in the Ohio and Mississippi River valleys, blastomycosis in the southeastern and midwestern US, and coccidioidomycosis in the southwestern US. Parasitic causes are more common in young animals with high parasite exposure. Toxin-induced interstitial pneumonia is rare but may occur in agricultural or industrial settings. Overall, the incidence is not well-defined, but interstitial pneumonia accounts for a significant proportion of diffuse lung disease in small animal practice.

The pathophysiology of interstitial pneumonia involves injury to the alveolar-capillary membrane, leading to inflammation and repair. Initial injury may be direct (e.g., viral cytolysis, toxin exposure) or indirect (e.g., immune-mediated). Viral infections often target alveolar epithelial cells and endothelial cells, causing necrosis and release of pro-inflammatory cytokines. This triggers recruitment of neutrophils, macrophages, and lymphocytes into the interstitium. In acute phases, there is edema, fibrin deposition, and hyaline membrane formation (diffuse alveolar damage). If the injury is severe or persistent, the inflammatory response becomes chronic, with proliferation of fibroblasts and deposition of collagen, leading to fibrosis. This disrupts normal gas exchange, causing ventilation-perfusion mismatch and hypoxemia. In chronic cases, there is architectural distortion of the lung, with honeycombing and bronchiolectasis. The disease may also cause pulmonary hypertension and cor pulmonale in advanced stages. The immune response can be exaggerated, leading to further tissue damage, as seen in immune-mediated interstitial pneumonia.

Predisposing factors for interstitial pneumonia include age (young animals for viral infections, older animals for idiopathic fibrosis), immune status (immunosuppression increases risk of Pneumocystis and fungal infections), vaccination status (unvaccinated animals are at higher risk for viral diseases), environmental factors (exposure to toxins, smoke, or dust), and concurrent diseases (e.g., chronic bronchitis, heart disease). Genetic factors play a role in breed-specific forms, such as the NAPS1 gene mutation in West Highland White Terriers with IPF. Stress, overcrowding, and poor ventilation increase the risk of respiratory infections. Certain medications (e.g., chemotherapeutic agents) can predispose to drug-induced interstitial pneumonia. In cats, chronic inflammation from asthma may progress to interstitial changes.

Clinical signs of interstitial pneumonia vary with the severity and chronicity. In peracute cases, animals may present with severe respiratory distress, tachypnea, cyanosis, and collapse. Acute cases often show fever, lethargy, anorexia, and a dry, non-productive cough (especially in cats). Subacute and chronic cases may have progressive exercise intolerance, weight loss, and a chronic cough. On physical examination, lung sounds may be normal or have crackles (especially in chronic fibrosis) and increased bronchovesicular sounds. In severe cases, there may be increased respiratory effort with abdominal breathing. Cats may exhibit open-mouth breathing and are often dyspneic. Systemic signs depend on the underlying cause: viral infections may be accompanied by ocular and nasal discharge, gastrointestinal signs, or neurologic signs (e.g., distemper). Fungal infections may have skin lesions, lameness, or ocular involvement. In chronic cases, signs of right-sided heart failure (e.g., ascites, jugular distension) may develop due to cor pulmonale.

Differential diagnoses for interstitial pneumonia include: 1) Pulmonary edema (cardiogenic or non-cardiogenic) – distinguished by heart enlargement, left atrial dilation, and response to diuretics; 2) Bronchopneumonia – characterized by alveolar infiltrates and productive cough, often with fever and leukocytosis; 3) Eosinophilic bronchopneumopathy – peripheral eosinophilia, bronchoalveolar lavage (BAL) eosinophilia, and response to corticosteroids; 4) Pulmonary neoplasia (e.g., bronchoalveolar carcinoma, lymphoma) – often nodular or mass-like lesions, cytology/histopathology confirms; 5) Pulmonary fibrosis (idiopathic) – chronic, progressive, with characteristic radiographic and CT findings, and histopathology; 6) Pulmonary thromboembolism – acute onset, risk factors (e.g., hyperadrenocorticism, heart disease), and imaging (CT angiography) shows filling defects; 7) Parasitic pneumonia (e.g., lungworms) – BAL or fecal examination for larvae; 8) Fungal pneumonia – serology, antigen testing, and cytology/histopathology; 9) Aspiration pneumonia – history of vomiting or dysphagia, dependent lung lobe distribution; 10) Acute respiratory distress syndrome (ARDS) – severe, acute onset, with known trigger (e.g., sepsis, trauma).

The diagnostic approach to interstitial pneumonia should be systematic. Step 1: Obtain a thorough history and physical examination, including respiratory rate and effort, auscultation, and assessment of mucous membranes. Step 2: Perform baseline bloodwork (CBC, serum biochemistry, and urinalysis) to identify inflammatory, infectious, or metabolic abnormalities. Step 3: Obtain thoracic radiographs (three views: right lateral, left lateral, and ventrodorsal or dorsoventral) to characterize the pulmonary pattern. Interstitial pattern is often diffuse, with increased opacity and loss of vascular clarity. Step 4: If radiographs are inconclusive or if chronic disease is suspected, consider advanced imaging (CT) for better characterization. Step 5: Perform arterial blood gas analysis to assess oxygenation and acid-base status. Step 6: Collect samples for cytology and culture via bronchoalveolar lavage (BAL) or tracheal wash, especially if infectious or inflammatory causes are suspected. Step 7: Consider specific infectious disease testing (e.g., PCR for viral agents, serology for fungi, antigen tests for Pneumocystis or heartworm). Step 8: If the diagnosis remains unclear, consider lung biopsy (via thoracoscopy or surgery) for histopathology. Step 9: In cases of suspected cardiac disease, perform echocardiography. Step 10: Based on findings, initiate appropriate therapy and monitor response.

Laboratory findings in interstitial pneumonia are often non-specific but may support the diagnosis. Hematology may show leukocytosis with a left shift in bacterial infections, lymphopenia in viral infections, or eosinophilia in parasitic or eosinophilic lung disease. Anemia may be present in chronic disease or with blood loss. Serum biochemistry may reveal hypoalbuminemia due to chronic inflammation, hyperglobulinemia in fungal or immune-mediated disease, and elevated liver enzymes if there is concurrent systemic involvement. Blood gas analysis typically shows hypoxemia (decreased PaO2) and possibly hypocapnia (due to hyperventilation) or hypercapnia in severe cases. Specific biomarkers: C-reactive protein (CRP) may be elevated in inflammatory conditions; procalcitonin may be useful in bacterial infections; NT-proBNP can help differentiate cardiac from respiratory causes. Serology and PCR are essential for specific infectious etiologies: e.g., canine distemper virus PCR, feline coronavirus PCR (for FIP), Histoplasma antigen testing, Blastomyces antigen testing, and Pneumocystis PCR. In cats, FIV/FeLV testing is recommended. Urinalysis may show proteinuria or casts in systemic diseases.

Thoracic radiography is the primary imaging modality. In interstitial pneumonia, the typical pattern is a diffuse unstructured interstitial pattern, characterized by increased pulmonary opacity with a hazy or reticular appearance, often most prominent in the caudodorsal lung fields. In acute cases, there may be a mixed alveolar-interstitial pattern. In chronic cases, there may be a reticular or linear pattern, and in severe fibrosis, there may be a honeycomb pattern with cystic lucencies. Radiographs may also show bronchial wall thickening (peribronchial cuffing) and, in some cases, a bronchointerstitial pattern. Ultrasonography of the lungs can reveal B-lines (comet-tail artifacts) indicating interstitial syndrome, but it is less specific. Computed tomography (CT) is more sensitive and can show ground-glass opacities, consolidation, reticular patterns, and traction bronchiectasis in fibrosis. CT is particularly useful for detecting early disease and for guiding biopsy. Magnetic resonance imaging (MRI) is rarely used for lung evaluation due to motion artifacts. Fluoroscopy may be used to assess dynamic airway collapse but is not specific for interstitial disease. Echocardiography is indicated if cardiac disease is suspected, to evaluate for left atrial enlargement or pulmonary hypertension.

Cytology from bronchoalveolar lavage (BAL) or tracheal wash is crucial for diagnosis. In interstitial pneumonia, BAL fluid may show increased cellularity with neutrophils, macrophages, and lymphocytes. In viral infections, there may be lymphocytic inflammation; in bacterial infections, neutrophilic inflammation with intracellular bacteria; in eosinophilic disease, >20% eosinophils; in fungal infections, organisms may be seen (e.g., Histoplasma yeast, Blastomyces broad-based budding yeast). Pneumocystis organisms can be identified with special stains (e.g., Diff-Quik, Gomori methenamine silver). Histopathology from lung biopsy is the gold standard. Acute interstitial pneumonia shows diffuse alveolar damage with hyaline membranes, edema, and inflammatory infiltrates. Chronic cases show interstitial fibrosis with collagen deposition, smooth muscle hyperplasia, and type II pneumocyte hyperplasia. Special stains (Masson trichrome for collagen, periodic acid-Schiff for fungi) can aid in diagnosis. In idiopathic pulmonary fibrosis, there is a characteristic pattern of temporally heterogeneous fibrosis with fibroblastic foci.

Treatment of interstitial pneumonia depends on the underlying cause and severity. Emergency stabilization is essential for hypoxemic animals: provide supplemental oxygen (via cage, flow-by, or nasal cannula) to maintain SpO2 > 94%. In severe respiratory distress, consider mechanical ventilation. Fluid therapy should be cautious to avoid fluid overload; use crystalloids at maintenance rates (e.g., 40-60 ml/kg/day) and monitor for pulmonary edema. Specific therapy: For bacterial infections, use appropriate antibiotics based on culture and sensitivity; common choices include amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h), doxycycline (5-10 mg/kg PO q12h), or fluoroquinolones (e.g., enrofloxacin 5-10 mg/kg PO/IV q24h). For viral infections, supportive care is primary; consider antiviral drugs (e.g., oseltamivir for influenza, but efficacy is unproven). For fungal infections, use antifungal agents: itraconazole (5-10 mg/kg PO q12-24h), fluconazole (5-10 mg/kg PO q12-24h), or amphotericin B (0.25-0.5 mg/kg IV three times weekly). For Pneumocystis, use trimethoprim-sulfamethoxazole (15-30 mg/kg PO q12h). For parasitic causes, use appropriate anthelmintics (e.g., fenbendazole 50 mg/kg PO q24h for 3-5 days). For immune-mediated or idiopathic interstitial pneumonia, corticosteroids are often used: prednisone (0.5-1 mg/kg PO q12h, tapering over weeks to months). In severe cases, immunosuppressive drugs like cyclosporine (5-10 mg/kg PO q12h) or azathioprine (2 mg/kg PO q24h) may be added. For pulmonary fibrosis, there is no cure; treatment is supportive with corticosteroids, bronchodilators (e.g., theophylline 10-20 mg/kg PO q12h), and antitussives (e.g., butorphanol 0.05-0.1 mg/kg PO q8-12h). Antifibrotic agents like pirfenidone are not well-studied in veterinary medicine. Supportive care includes nutritional support, rest, and minimizing stress. In cases of cor pulmonale, treat with sildenafil (1-2 mg/kg PO q8-12h) for pulmonary hypertension.

The prognosis for interstitial pneumonia varies widely depending on the cause and severity. Acute viral or bacterial interstitial pneumonia has a fair to good prognosis if treated early and aggressively, with recovery in 1-2 weeks. Fungal pneumonia has a guarded prognosis, with a response rate of 60-70% but requiring long-term therapy (6-12 months) and potential relapse. Parasitic pneumonia has a good prognosis with appropriate deworming. Idiopathic pulmonary fibrosis has a poor prognosis, with a median survival time of 6-12 months in dogs and 3-6 months in cats after diagnosis. Negative prognostic indicators include severe hypoxemia (PaO2 < 60 mmHg), need for mechanical ventilation, presence of cor pulmonale, and lack of response to therapy within 48-72 hours. Chronic cases with fibrosis have a progressive course, and quality of life may decline despite treatment.

Follow-up is essential to monitor response to therapy and adjust treatment. Recheck examinations should be performed at 1-2 weeks after initiation of therapy, then monthly until resolution. Serial thoracic radiographs should be taken every 2-4 weeks to assess resolution of pulmonary infiltrates. Blood gas analysis should be repeated to monitor oxygenation. For infectious diseases, repeat antigen or PCR testing may be needed to confirm clearance. For chronic diseases, long-term monitoring every 3-6 months is recommended. Adjust drug dosages based on clinical response and side effects. For corticosteroid therapy, taper gradually to avoid relapse. For antifungal therapy, monitor liver enzymes and drug levels (e.g., itraconazole) to avoid toxicity. Provide client education on recognizing signs of respiratory distress and the importance of compliance.

Pearls: 1) Always consider interstitial pneumonia in any animal with a non-productive cough and tachypnea, especially if radiographs show a diffuse interstitial pattern. 2) In cats, interstitial pneumonia is often associated with viral infections or asthma; perform a thorough diagnostic workup. 3) Use CT for early detection of fibrosis when radiographs are inconclusive. 4) BAL is essential for cytology and culture; do not rely solely on tracheal wash. 5) In acute respiratory distress, provide oxygen immediately and avoid excessive handling. Pitfalls: 1) Do not use corticosteroids in infectious interstitial pneumonia without appropriate antimicrobial therapy, as it can worsen the infection. 2) Avoid overhydration with IV fluids, which can exacerbate pulmonary edema. 3) Do not assume that an interstitial pattern is always non-cardiogenic; rule out heart disease with echocardiography. 4) Failure to perform a lung biopsy in chronic cases may lead to misdiagnosis and inappropriate treatment. 5) Do not discontinue antifungal therapy prematurely, as relapse is common.

Antimicrobials: Amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) for bacterial pneumonia; Doxycycline (5-10 mg/kg PO q12h) for Mycoplasma and Rickettsial; Enrofloxacin (5-10 mg/kg PO/IV q24h) for Gram-negative infections; Azithromycin (5-10 mg/kg PO q24h) for Bordetella and Mycoplasma. Antifungals: Itraconazole (5-10 mg/kg PO q12-24h) for Histoplasma, Blastomyces; Fluconazole (5-10 mg/kg PO q12-24h) for Coccidioides; Amphotericin B (0.25-0.5 mg/kg IV three times weekly) for severe systemic mycoses. Antiparasitics: Fenbendazole (50 mg/kg PO q24h for 3-5 days) for lungworms; Ivermectin (0.2-0.4 mg/kg SC or PO) for heartworm microfilaria (with caution in collies). Immunosuppressants: Prednisone (0.5-1 mg/kg PO q12h, tapering) for immune-mediated disease; Cyclosporine (5-10 mg/kg PO q12h) for refractory cases; Azathioprine (2 mg/kg PO q24h) for steroid-sparing. Bronchodilators: Theophylline (10-20 mg/kg PO q12h) for chronic bronchitis; Terbutaline (0.01 mg/kg SC or 0.625-1.25 mg/cat PO q8-12h) for acute bronchospasm. Antitussives: Butorphanol (0.05-0.1 mg/kg PO q8-12h) for severe cough; Hydrocodone (0.22 mg/kg PO q8-12h) for chronic cough. Pulmonary hypertension: Sildenafil (1-2 mg/kg PO q8-12h). Oxygen therapy: 40-60% inspired oxygen via cage or nasal cannula. Fluid therapy: Balanced crystalloids at 40-60 ml/kg/day, adjusted based on hydration and urine output.

Evidence-based literature on interstitial pneumonia in dogs and cats is limited, but several studies provide guidance. A retrospective study by Johnson et al. (2004) described clinical findings and outcomes in dogs with interstitial lung disease, noting that histopathology is necessary for definitive diagnosis. In cats, a study by Cohn et al. (2010) evaluated CT features of interstitial pneumonia and found ground-glass opacities to be common. The ACVIM consensus statement on the diagnosis and treatment of canine and feline pulmonary disease (2015) emphasizes the importance of BAL and CT in diagnosing interstitial pneumonia. For idiopathic pulmonary fibrosis in West Highland White Terriers, a study by Heikkilä et al. (2011) identified a genetic mutation associated with the disease. Treatment recommendations are largely extrapolated from human medicine and small case series. A randomized controlled trial by Dear et al. (2018) evaluated the use of sildenafil for pulmonary hypertension secondary to respiratory disease, showing improved exercise tolerance. Overall, there is a need for more prospective studies to establish standardized treatment protocols.